{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:39:49Z","timestamp":1787585989655,"version":"build-2736575974"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program","doi-asserted-by":"crossref","award":["2018YFE0113900"],"award-info":[{"award-number":["2018YFE0113900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870662"],"award-info":[{"award-number":["81870662"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s10384-022-00932-1","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T17:07:39Z","timestamp":1659114459000},"page":"405-412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Update on glial antibody-mediated optic neuritis"],"prefix":"10.1007","volume":"66","author":[{"given":"Honglu","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanfen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"key":"932_CR1","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199202273260901","volume":"326","author":"RW Beck","year":"1992","unstructured":"Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326:581\u20138.","journal-title":"N Engl J Med"},{"key":"932_CR2","first-page":"727","volume":"65","author":"Optic Neuritis Study Group","year":"2008","unstructured":"Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65:727\u201332.","journal-title":"Arch Neurol"},{"key":"932_CR3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamaophthalmol.2017.6757","volume":"136","author":"JJ Chen","year":"2018","unstructured":"Chen JJ, Tobin WO, Majed M, Jitprapaikulsan J, Fryer JP, Leavitt JA, et al. Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the optic neuritis treatment trial. JAMA Ophthalmol. 2018;136:419\u201322.","journal-title":"JAMA Ophthalmol."},{"key":"932_CR4","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106\u201312.","journal-title":"Lancet"},{"key":"932_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473\u20137.","journal-title":"J Exp Med"},{"key":"932_CR6","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485\u20139.","journal-title":"Neurology"},{"key":"932_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177\u201389.","journal-title":"Neurology"},{"key":"932_CR8","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000110","volume":"2","author":"A Zekeridou","year":"2015","unstructured":"Zekeridou A, Lennon VA. Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm. 2015;2: e110.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"932_CR9","first-page":"4025","volume":"130","author":"T Chen","year":"2020","unstructured":"Chen T, Lennon VA, Liu YU, Bosco DB, Li Y, Yi M-H, et al. Astrocyte-microglia interaction drives evolving neuromyelitis optica lesion. J Clin Invest. 2020;130:4025\u201338.","journal-title":"J Clin Invest"},{"key":"932_CR10","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","volume":"78","author":"PJ Waters","year":"2012","unstructured":"Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012;78:665\u201371 (Discussion 9).","journal-title":"Neurology."},{"key":"932_CR11","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","volume":"81","author":"Y Jiao","year":"2013","unstructured":"Jiao Y, Fryer JP, Lennon VA, Jenkins SM, Quek AML, Smith CY, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013;81:1197\u2013204.","journal-title":"Neurology"},{"key":"932_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13317-019-0115-7","volume":"10","author":"M Tampoia","year":"2019","unstructured":"Tampoia M, Abbracciavento L, Barberio G, Fabris M, Bizzaro N, Study Group on Autoimmune Diseases of the Italian Society of Clinical Pathology and Laboratory Medicine, Italy. A new M23-based ELISA assay for anti-aquaporin 4 autoantibodies: diagnostic accuracy and clinical correlation. Autoimmun Highlights. 2019;10:5.","journal-title":"Autoimmun Highlights."},{"key":"932_CR13","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1136\/bjophthalmol-2017-311177","volume":"102","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Tan S, Chan TCY, Xu Q, Zhao J, Teng D, et al. Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients. Br J Ophthalmol. 2018;102:1372\u20137.","journal-title":"Br J Ophthalmol"},{"key":"932_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","volume":"15","author":"M Reindl","year":"2019","unstructured":"Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nature Rev Neurol. 2019;15:89\u2013102.","journal-title":"Nature Rev Neurol."},{"key":"932_CR15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflamm. 2018;15:134.","journal-title":"J Neuroinflamm"},{"key":"932_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12974-018-1108-6","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Ruprecht K, Stellmann JP, Huss A, Ayzenberg I, Willing A, et al. MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature. J Neuroinflamm. 2018;15:88.","journal-title":"J Neuroinflamm"},{"key":"932_CR17","doi-asserted-by":"publisher","first-page":"175628641876208","DOI":"10.1177\/1756286418762083","volume":"11","author":"MS Weber","year":"2018","unstructured":"Weber MS, Derfuss T, Metz I, Br\u00fcck W. Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Ther Adv Neurol Disord. 2018;11:1756286418762083.","journal-title":"Ther Adv Neurol Disord"},{"key":"932_CR18","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1177\/1352458515622986","volume":"22","author":"S Jarius","year":"2016","unstructured":"Jarius S, Metz I, K\u00f6nig FB, Ruprecht K, Reindl M, Paul F, et al. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in \u201cpattern II multiple sclerosis\u201d and brain biopsy findings in a MOG-IgG-positive case. Mult Scler. 2016;22:1541\u20139.","journal-title":"Mult Scler"},{"key":"932_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bpa.12099","volume":"24","author":"CF Lucchinetti","year":"2014","unstructured":"Lucchinetti CF, Guo Y, Popescu BFG, Fujihara K, Itoyama Y, Misu T. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol. 2014;24:83\u201397.","journal-title":"Brain Pathol"},{"key":"932_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/acn3.164","volume":"2","author":"M Spadaro","year":"2015","unstructured":"Spadaro M, Gerdes LA, Mayer MC, Ertl-Wagner B, Laurent S, Krumbholz M, et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol. 2015;2:295\u2013301.","journal-title":"Ann Clin Transl Neurol"},{"key":"932_CR21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/WNO.0000000000000779","volume":"39","author":"JJ Chen","year":"2019","unstructured":"Chen JJ, Fraser CL. Do myelin oligodendrocyte glycoprotein antibodies represent a distinct syndrome? J Neuro-Ophthalmol. 2019;39:416\u201323.","journal-title":"J Neuro-Ophthalmol."},{"key":"932_CR22","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","volume":"75","author":"AS L\u00f3pez-Chiriboga","year":"2018","unstructured":"L\u00f3pez-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol. 2018;75:1355\u201363.","journal-title":"JAMA Neurol"},{"key":"932_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm. 2016;13:280.","journal-title":"J Neuroinflamm."},{"key":"932_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021238","volume":"99","author":"L Du","year":"2020","unstructured":"Du L, Wang H, Zhou H, Chang H, Wei Y, Cong H, et al. Anti-NMDA receptor encephalitis concomitant with myelin oligodendrocyte glycoprotein antibody diseases: a retrospective observational study. Medicine. 2020;99: e21238.","journal-title":"Medicine"},{"key":"932_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","volume":"76","author":"D Dubey","year":"2019","unstructured":"Dubey D, Pittock SJ, Krecke KN, Morris PP, Sechi E, Zalewski NL, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol. 2019;76:301\u20139.","journal-title":"JAMA Neurol"},{"key":"932_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","volume":"195","author":"JJ Chen","year":"2018","unstructured":"Chen JJ, Flanagan EP, Jitprapaikulsan J, L\u00f3pez-Chiriboga ASS, Fryer JP, Leavitt JA, et al. Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol. 2018;195:8\u201315.","journal-title":"Am J Ophthalmol"},{"key":"932_CR27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflamm. 2016;13:279.","journal-title":"J Neuroinflamm."},{"key":"932_CR28","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/bjophthalmol-2018-312399","volume":"103","author":"H Song","year":"2019","unstructured":"Song H, Zhou H, Yang M, Tan S, Wang J, Xu Q, et al. Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China. Br J Ophthalmol. 2019;103:831\u20136.","journal-title":"Br J Ophthalmol"},{"key":"932_CR29","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjophthalmol-2020-317524","volume":"106","author":"M Yang","year":"2022","unstructured":"Yang M, Wu Y, Lai M, Song H, Li H, Sun M, et al. Clinical predictive factors for diagnosis of MOG-IgG and AQP4-IgG related paediatric optic neuritis: a Chinese cohort study. Br J Ophthalmol. 2022;106:262\u20136.","journal-title":"Br J Ophthalmol"},{"key":"932_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ajo.2022.01.015","volume":"239","author":"M Yang","year":"2022","unstructured":"Yang M, Wu Y, Song H, Lai M, Li H, Sun M, et al. Vision prognosis and associated factors of optic neuritis in dependence of glial autoimmune antibodies. Am J Ophthalmol. 2022;239:11\u201325.","journal-title":"Am J Ophthalmol"},{"key":"932_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jns.2019.03.014","volume":"400","author":"H Song","year":"2019","unstructured":"Song H, Zhou H, Yang M, Xu Q, Sun M, Wei S. Clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis in varying age groups: a cohort study in China. J Neurol Sci. 2019;400:83\u20139.","journal-title":"J Neurol Sci"},{"key":"932_CR32","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/bjophthalmol-2018-313142","volume":"103","author":"H Liu","year":"2019","unstructured":"Liu H, Zhou H, Wang J, Xu Q, Wei S. Antibodies to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy. Br J Ophthalmol. 2019;103:1423\u20138.","journal-title":"Br J Ophthalmol"},{"key":"932_CR33","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12974-018-1335-x","volume":"15","author":"HJ Lee","year":"2018","unstructured":"Lee HJ, Kim B, Waters P, Woodhall M, Irani S, Ahn S, et al. Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies. J Neuroinflamm. 2018;15:302.","journal-title":"J Neuroinflamm"},{"key":"932_CR34","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jns.2018.11.029","volume":"396","author":"H Liu","year":"2019","unstructured":"Liu H, Zhou H, Wang J, Sun M, Teng D, Song H, et al. The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis. J Neurol Sci. 2019;396:225\u201331.","journal-title":"J Neurol Sci"},{"key":"932_CR35","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140:3128\u201338.","journal-title":"Brain"},{"key":"932_CR36","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.ophtha.2018.03.041","volume":"125","author":"J Jitprapaikulsan","year":"2018","unstructured":"Jitprapaikulsan J, Chen JJ, Flanagan EP, Tobin WO, Fryer JP, Weinshenker BG, et al. Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis. Ophthalmology. 2018;125:1628\u201337.","journal-title":"Ophthalmology"},{"key":"932_CR37","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jns.2010.07.011","volume":"298","author":"S Jarius","year":"2010","unstructured":"Jarius S, Frederikson J, Waters P, Paul F, Akman-Demir G, Marignier R, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci. 2010;298:158\u201362.","journal-title":"J Neurol Sci"},{"key":"932_CR38","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1136\/jnnp-2014-310206","volume":"87","author":"T Akaishi","year":"2016","unstructured":"Akaishi T, Sato DK, Nakashima I, Takeshita T, Takahashi T, Doi H, et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study. J Neurol Neurosurg Psychiatry. 2016;87:446\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"932_CR39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1148\/rg.2018170141","volume":"38","author":"BG Dutra","year":"2018","unstructured":"Dutra BG, da Rocha AJ, Nunes RH, Maia ACM Jr. Neuromyelitis optica spectrum disorders: spectrum of MR imaging findings and their differential diagnosis. Radiographics. 2018;38:169\u201393.","journal-title":"Radiographics"},{"key":"932_CR40","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s41433-020-01334-8","volume":"35","author":"SM Gospe","year":"2021","unstructured":"Gospe SM, Chen JJ, Bhatti MT. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. Eye (Lond). 2021;35:753\u201368.","journal-title":"Eye (Lond)"},{"key":"932_CR41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.survophthal.2019.08.001","volume":"65","author":"JJ Chen","year":"2020","unstructured":"Chen JJ, Pittock SJ, Flanagan EP, Lennon VA, Bhatti MT. Optic neuritis in the era of biomarkers. Surv Ophthalmol. 2020;65:12\u20137.","journal-title":"Surv Ophthalmol"},{"key":"932_CR42","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10384-021-00840-w","volume":"65","author":"M Nakazawa","year":"2021","unstructured":"Nakazawa M, Ishikawa H, Sakamoto T. Current understanding of the epidemiologic and clinical characteristics of optic neuritis. Jpn J Ophthalmol. 2021;65:439\u201347.","journal-title":"Jpn J Ophthalmol"},{"key":"932_CR43","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000572","volume":"6","author":"H Stiebel-Kalish","year":"2019","unstructured":"Stiebel-Kalish H, Hellmann MA, Mimouni M, Paul F, Bialer O, Bach M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm. 2019;6: e572.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"932_CR44","doi-asserted-by":"publisher","first-page":"175628642094797","DOI":"10.1177\/1756286420947977","volume":"13","author":"S Tan","year":"2020","unstructured":"Tan S, Ng TK, Xu Q, Yang M, Zhuang Y, Zhao J, et al. Vision improvement in severe acute isolated optic neuritis after plasma exchange treatment in Chinese population: a prospective case series study. Ther Adv Neurol Disord. 2020;13:1756286420947977.","journal-title":"Ther Adv Neurol Disord"},{"key":"932_CR45","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000504","volume":"5","author":"I Kleiter","year":"2018","unstructured":"Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, et al. Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm. 2018;5: e504.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"932_CR46","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1352458515581438","volume":"22","author":"H Abboud","year":"2016","unstructured":"Abboud H, Petrak A, Mealy M, Sasidharan S, Siddique L, Levy M. Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler. 2016;22:185\u201392.","journal-title":"Mult Scler"},{"key":"932_CR47","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jneuroim.2015.03.021","volume":"282","author":"S Viswanathan","year":"2015","unstructured":"Viswanathan S, Wong AHY, Quek AML, Yuki N. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica. J Neuroimmunol. 2015;282:92\u20136.","journal-title":"J Neuroimmunol"},{"key":"932_CR48","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejpn.2020.10.005","volume":"29","author":"AL Bruijstens","year":"2020","unstructured":"Bruijstens AL, Wendel E-M, Lechner C, Bartels F, Finke C, Breu M, et al. E.U. paediatric MOG consortium consensus: part 5\u2014treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020;29:41\u201353.","journal-title":"Eur J Paediatr Neurol."},{"key":"932_CR49","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s10384-020-00790-9","volume":"65","author":"O Mimura","year":"2021","unstructured":"Mimura O, Ishikawa H, Kezuka T, Shikishima K, Suzuki T, Nakamura M, et al. Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: a multicenter, double-blind, randomized, controlled phase III study. Jpn J Ophthalmol. 2021;65:122\u201332.","journal-title":"Jpn J Ophthalmol"},{"key":"932_CR50","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","volume":"10","author":"MC Papadopoulos","year":"2014","unstructured":"Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol. 2014;10:493\u2013506.","journal-title":"Nat Rev Neurol"},{"key":"932_CR51","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","volume":"17","author":"J Sellner","year":"2010","unstructured":"Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17:1019\u201332.","journal-title":"Eur J Neurol"},{"key":"932_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102428","volume":"45","author":"E Carnero Contentti","year":"2020","unstructured":"Carnero Contentti E, Rojas JI, Cristiano E, Marques VD, Flores-Rivera J, Lana-Peixoto M, et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Mult Scler RelatDisord. 2020;45: 102428.","journal-title":"Mult Scler RelatDisord."},{"key":"932_CR53","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","volume":"264","author":"Z Nikoo","year":"2017","unstructured":"Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017;264:2003\u20139.","journal-title":"J Neurol"},{"key":"932_CR54","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19:298\u2013306.","journal-title":"Lancet Neurol"},{"key":"932_CR55","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. New Eng J Med. 2019;381:614\u201325.","journal-title":"New Eng J Med."},{"key":"932_CR56","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet. 2019;394:1352\u201363.","journal-title":"Lancet"},{"key":"932_CR57","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19:402\u201312.","journal-title":"Lancet Neurol"},{"key":"932_CR58","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. New Eng J Med. 2019;381:2114\u201324.","journal-title":"New Eng J Med."},{"key":"932_CR59","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","volume":"19","author":"C Zhang","year":"2020","unstructured":"Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19:391\u2013401.","journal-title":"Lancet Neurol"},{"key":"932_CR60","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000705","volume":"7","author":"S Li","year":"2020","unstructured":"Li S, Ren H, Xu Y, Xu T, Zhang Y, Yin H, et al. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: a prospective study. Neurol Neuroimmunol Neuroinflamm. 2020;7: e705.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"932_CR61","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-019-1525-1","volume":"16","author":"A Cobo-Calvo","year":"2019","unstructured":"Cobo-Calvo A, Sep\u00falveda M, Rollot F, Armangu\u00e9 T, Ruiz A, Maillart E, et al. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflamm. 2019;16:134.","journal-title":"J Neuroinflamm"},{"key":"932_CR62","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","volume":"75","author":"Y Hacohen","year":"2018","unstructured":"Hacohen Y, Wong YY, Lechner C, Jurynczyk M, Wright S, Konuskan B, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol. 2018;75:478\u201387.","journal-title":"JAMA Neurol"},{"key":"932_CR63","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","volume":"89","author":"S Ramanathan","year":"2018","unstructured":"Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89:127\u201337.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"932_CR64","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","volume":"95","author":"JJ Chen","year":"2020","unstructured":"Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga ASS, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020;95:e111\u201320.","journal-title":"Neurology"},{"key":"932_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2022.577812","volume":"364","author":"G Nepal","year":"2022","unstructured":"Nepal G, Kharel S, Coghlan MA, Rayamajhi P, Ojha R. Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): a systematic review and meta-analysis. J Neuroimmunol. 2022;364: 577812.","journal-title":"J Neuroimmunol"},{"key":"932_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103310","volume":"56","author":"S Thakolwiboon","year":"2021","unstructured":"Thakolwiboon S, Zhao-Fleming H, Karukote A, Mao-Draayer Y, Flanagan EP, Avila M. Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder. Mult Sclerosis Relat Disord. 2021;56: 103310.","journal-title":"Mult Sclerosis Relat Disord."},{"key":"932_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102251","volume":"44","author":"DH Whittam","year":"2020","unstructured":"Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, Pardo S, Gornall M, Cicconi S, et al. Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Mult Sclerosis Relat Disord. 2020;44: 102251.","journal-title":"Mult Sclerosis Relat Disord."},{"key":"932_CR68","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-318769","author":"L Xie","year":"2021","unstructured":"Xie L, Zhou H, Song H, Sun M, Yang M, Lai YM, et al. Comparative analysis of immunosuppressive therapies for myelin oligodendrocyte glycoprotein antibody-associated optic neuritis: a cohort study. Br J Ophthalmol. 2021. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-318769.","journal-title":"Br J Ophthalmol."},{"key":"932_CR69","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1212\/WNL.0000000000007312","volume":"92","author":"H Hayward-Koennecke","year":"2019","unstructured":"Hayward-Koennecke H, Reindl M, Martin R, Schippling S. Tocilizumab treatment in severe recurrent anti-MOG-associated optic neuritis. Neurology. 2019;92:765\u20137.","journal-title":"Neurology"},{"key":"932_CR70","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001100","volume":"9","author":"M Ringelstein","year":"2022","unstructured":"Ringelstein M, Ayzenberg I, Lindenblatt G, Fischer K, Gahlen A, Novi G, et al. Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2022;9: e1100. https:\/\/doi.org\/10.1212\/NXI.0000000000001100.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"932_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","volume":"261","author":"C Trebst","year":"2014","unstructured":"Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis optica study group (NEMOS). J Neurol. 2014;261:1\u201316.","journal-title":"J Neurol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-022-00932-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-022-00932-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-022-00932-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T09:22:32Z","timestamp":1661419352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-022-00932-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["932"],"URL":"https:\/\/doi.org\/10.1007\/s10384-022-00932-1","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,27]]},"assertion":[{"value":"22 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H. Song, None; H. Zhou, None; S. Wei, None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}